Invesco
XENE icon

Invesco’s Xenon Pharmaceuticals XENE Stock Holding History

Invesco’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.5M Buy
903,458
+844,355
+1,429% +$46.9M ﹤0.01% 1083
2026
Q1 		$3.44M Buy
59,103
+8,156
+16% +$376K ﹤0.01% 2326
2025
Q4 		$2.28M Sell
50,947
-5,117
-9% -$215K ﹤0.01% 2561
2025
Q3 		$2.25M Sell
56,064
-3,534
-6% -$124K ﹤0.01% 2571
2025
Q2 		$1.87M Sell
59,598
-146,165
-71% -$4.77M ﹤0.01% 2595
2025
Q1 		$6.9M Sell
205,763
-3,791
-2% -$144K ﹤0.01% 1996
2024
Q4 		$8.21M Sell
209,554
-6,268
-3% -$259K ﹤0.01% 1974
2024
Q3 		$8.5M Sell
215,822
-650,963
-75% -$26.2M ﹤0.01% 1933
2024
Q2 		$33.8M Sell
866,785
-182,741
-17% -$7.3M 0.01% 1177
2024
Q1 		$45.2M Buy
1,049,526
+329,808
+46% +$15.2M 0.01% 1085
2023
Q4 		$33.2M Buy
719,718
+3,415
+0.5% +$121K 0.01% 1188
2023
Q3 		$24.5M Buy
716,303
+16,318
+2% +$610K 0.01% 1249
2023
Q2 		$26.9M Buy
699,985
+683,514
+4,150% +$27.2M 0.01% 1201
2023
Q1 		$589K Buy
+16,471
New +$608K ﹤0.01% 3172
2022
Q2 		– Sell
-198,701
Closed -$6.07M – 4157
2022
Q1 		$6.07M Sell
198,701
-95,399
-32% -$2.86M ﹤0.01% 2276
2021
Q4 		$9.19M Buy
+294,100
New +$8.79M ﹤0.01% 2057
2020
Q1 		– Sell
-12,410
Closed -$163K – 3735
2019
Q4 		$163K Buy
12,410
+1,865
+18% +$19.6K ﹤0.01% 3555
2019
Q3 		$95K Sell
10,545
-3,313
-24% -$31.3K ﹤0.01% 3629
2019
Q2 		$137K Buy
+13,858
New +$133K ﹤0.01% 3657

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco's XENE Position: Q2 2026 in Review

Invesco increased its Xenon Pharmaceuticals (XENE) stake by 1,429% in Q2 2026, buying an estimated $46.9M and bringing the position to 903,458 shares worth $54.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1083.

Invesco first reported a position in XENE in Q2 2019 and has held it in 19 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Invesco held 903,458 shares of Xenon Pharmaceuticals worth $54.5M as of Q2 2026.
  • Invesco bought 844,355 Xenon Pharmaceuticals shares in Q2 2026, an estimated $46.9M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1083 holding.
  • Invesco first reported a position in Xenon Pharmaceuticals in Q2 2019 and has held it in 19 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.